Initiator Pharma A/S (STO:INIT)

Market Cap	180.72M -13.3%
Revenue (ttm)	n/a
Net Income	-33.16M
EPS	-0.51
Shares Out	68.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,464
Open	2.800
Previous Close	2.710
Day's Range	2.570 - 2.800
52-Week Range	2.530 - 4.170
Beta	0.06
Analysts	n/a
Price Target	8.06 (+205.3%)
Earnings Date	Aug 21, 2026

About Initiator Pharma

Initiator Pharma A/S, a clinical-stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous systems. The company is developing Pudafensine, a monoamine reuptake inhibitor that has completed a Phase IIb clinical trial primarily targeting the dopamine system for the treatment of treatment-resistant organic erectile dysfunction; a Phase IIa trial for the treatment of vulvodynia; and preclinical development for the treatment of female sexual dysfunction (FSD). It is also developing IP2018, a m...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: INIT

Financial Performance

Financial numbers in DKK